国常会审议通过《生物医学新技术临床研究和临床转化应用管理条例(草案)》

Core Viewpoint - The State Council of China, led by Premier Li Qiang, has approved the draft regulation for the management of clinical research and clinical application of biomedical new technologies, aiming to enhance innovation and development in the biomedical sector [1] Group 1: Innovation and Development - The meeting emphasized the need to promote innovation and development in China's biomedical technology [1] - There is a focus on accelerating technology research and the transformation of research outcomes into practical applications [1] - The goal is to enhance the quality and upgrade the biomedical industry, creating new competitive advantages [1] Group 2: Regulation and Safety - The regulation aims to ensure that clinical research is conducted in a legally compliant manner [1] - It is crucial to safeguard the quality and safety of clinical applications [1] - The initiative seeks to effectively prevent various risks associated with biomedical innovations [1] Group 3: Public Health - The ultimate objective is to ensure that innovative outcomes contribute positively to the health and well-being of the population [1]